novartis semaglutide Novo Nordisk 2022: Expanding capabilities Novo Nordisk asks FDA to

Finally, multivariable Cox regression analysis revealed that GSTM3 was a risk factor for OS among patients with PC (hazard ratio [HR] = 1.208, 95% confidence interval [CI]: 1.0221.608, P = 0.012) (Table 2)

The other co-primary outcome was patients achieving a 5% or greater reduction in weight from baseline to week 104, and this was achieved by 77% of semaglutide patients and 34% of placebo patients, a statistically significant difference between groups

Jan 6 2021;13(1)doi:10.3390/nu13010162

Hierarchical mechanisms control the clearance of DNA lesion-stalled RNA polymerase II

KPV: applied in mucosal and airway inflammation models to study epithelial barrier behavior and inflammatory signaling